狼肠炎中低剂量利图西马布:对其调节粘膜免疫力和减少炎症的疗效进行了比较研究
Ying Liu1, YuJie Pang2, Yang Liu2
1Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Arthritis research & therapy
|September 30, 2025
概括
利图西马布 (RTX) 加上葡萄糖皮质类药物和常规免疫抑制剂加上葡萄糖皮质类药物有效治疗狼肠炎 (LE). 两种疗法都实现了缓解,RTX显示出更快的生物标志物改善.
科学领域:
- 类风湿病学 类风湿病学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 狼肠炎 (LE) 是一种严重的全身性红斑狼 (SLE) 并发症,其最佳治疗方法尚不清楚.
- 这项研究比较Rituximab (RTX) 加上葡萄糖皮质激素与常规免疫抑制剂加上葡萄糖皮质激素对中度至严重的LE.
研究的目的:
- 为了比较RTX加糖皮质激素与常规免疫抑制剂加糖皮质激素在治疗狼肠炎中的疗效和安全性.
主要方法:
- 对36名患有肠道干扰的SLE患者的回顾性分析.
- 对RTX加上葡萄皮质激素 (n=16) 与常规免疫抑制剂加上葡萄皮质激素 (n=20) 的比较.
- 在6个月内对临床,成像,实验室 (IgA,IL-6,TNF-α,IL-10) 和疾病活性评分 (SLEDAI-2K,BILAG-2004) 的评估.
主要成果:
- 这两种治疗都显著改善了临床症状和成像检测结果 (肠壁加厚,介质流血等). ) 的情况.
- 6个月后缓解率没有显著差异 (93.8%的RTX与85%的控制).
- RTX组显示IL-6水平显著降低,SLEDAI-2K和BILAG-2004得分下降速度更快.
结论:
- 既RTX和常规免疫抑制剂与葡萄皮质类药物对LE缓解是有效的.
- 在特定的炎症生物标志物中,RTX可能会提供更快的改善.
- 为了个性化治疗策略,需要对更大的队列和更长的随访进行进一步的研究.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
437
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
437
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
643
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
643
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521


